BEBT-109, A PAN-MUTANT-SELECTIVE EGFR INHIBITOR WITH POTENT ANTITUMOR ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer

OVEN LINER EGFR mutation-positive NSCLC tumors are highly heterogeneous, therefore, exploring an agent simultaneously targeting multiple EGFR mutations may be valuable for clinical practice.Compared with osimertinib, BEBT-109 shows more sensitive and extensive antitumor activity in EGFR mutant NSCLC, while sparing wild-type EGFR cell lines.Meanwhil

read more


Propofol alternatives in gastrointestinal endoscopy anesthesia

Although propofol has been the backbone for sedation in Day and Night Cream gastrointestinal endoscopy, both anesthesiologists and endoscopists are faced with situations where an alternative is needed.Recent national shortages forced many physicians to explore these options.A midazolam and fentanyl combination is the mainstay in this area.However,

read more